Calliditas Therapeutics AB (publ) provided revenue guidance for the year ending December 31, 2024. For the year, the company expects continued revenue growth: total net sales are estimated to be USD 150-180 million for the year ending December 31, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
115.3 SEK | +4.06% | +7.76% | -9.28% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.28% | 549M | |
+7.22% | 72.81B | |
+12.72% | 9.13B | |
-11.75% | 5.13B | |
+59.61% | 4.99B | |
+2.62% | 3.9B | |
-17.54% | 2.48B | |
+21.35% | 2.42B | |
-27.82% | 2.32B | |
+25.13% | 2.17B |
- Stock Market
- Equities
- CALTX Stock
- News Calliditas Therapeutics AB
- Calliditas Therapeutics AB Provides Revenue Guidance for the Year Ending December 31, 2024